Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: Implications for liposome-encapsulated daunorubicin

Verdonck, Leo F.; Lokhorst, Henk M.; Roovers, Dick J.; Heugten, Hans G. van

doi:10.1016/s0145-2126(97)00160-4

Cited by 22 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, liposomes have been used as carriers for many kinds of molecules such as anti-cancer [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25], antibacterial [26][27][28][29], anti-fungal [30,31] and anti-viral [32,33] agents, and bioactive macromolecules [34][35][36][37][38][39].…”

Section: Liposomesmentioning

confidence: 99%

Liposome-Nanogel Structures for Future Pharmaceutical Applications

Казаков¹,

Levón²

2006

CPD

View full text Add to dashboard Cite

Nanoparticles have been extensively studied as drug delivery systems. In this review, we focus on a relatively new type of nanoparticles--lipobeads--a liposome-hydrogel assembly as a novel drug delivery system. An appropriate assemblage of spherical hydrogel particles and liposomes combines the properties of both classes of materials and may find a variety of biomedical applications. The bi-compartmental structure of lipobeads is a natural configuration. Thus, the technology of their preparation can be a key step of designing more stable and effective vaccines. Biocompatibility and stability, ability to deliver a broad range of bioactive molecules, environmental responsiveness of both inner nanogel core and external lipid bilayer, and individual specificity of both compartments make the liposome-nanogel design a versatile drug delivery system relevant for all known drug administration routes and suitable for different diseases with possibility of efficient targeting to different organs. New findings on reversible and irreversible aggregation of lipobeads can lead to novel combined drug delivery systems regarding lipobeads as multipurpose containers. The research on hydrogel-liposome submicrometer structures has just begun and fundamental studies on interactions between hydrogels and liposomes are in demand.

show abstract

Section: Liposomesmentioning

confidence: 99%

Liposome-Nanogel Structures for Future Pharmaceutical Applications

Казаков¹,

Levón²

2006

CPD

View full text Add to dashboard Cite

show abstract

“…However, encapsulation of daunorubicin results in a favourable distribution pattern of the drug in animal models, indicating that the liposomes can be incorporated into tumour tissue [5]. In addition, in vitro studies suggest a higher activity of liposomal daunorubicin in leukaemia cell lines expressing high levels of P-glycoprotein (PgP) than conventional daunorubicin [15,16]. Some authors found that the phospholipids used for the preparation of the liposomes act directly as PgP-modulators [17].…”

Section: Discussionmentioning

confidence: 99%

Population pharmacokinetics of liposomal daunorubicin in children

Hempel

Reinhardt

Creutzig

et al. 2003

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimsTo investigate the population pharmacokinetics of daunorubicin in children after administration of liposomal daunorubicin (Daunoxome ® ). Methods Plasma samples from 19 children with relapsed acute myeloic leukaemia and five children with other malignancies were collected. Daunoxome ® was administered as a 1-to 2.5 h infusion with doses ranging from 30 to 60 mg m -2 . Overall, 214 samples were analysed for daunorubicin using capillary electrophoresis, and population pharmacokinetic modelling was performed using NONMEM. Results The data were best described by a one compartment model. Inclusion of interoccasion variability in the model (16.7% for clearance) improved strongly the precision of the estimates. The inclusion of body surface area or height as a covariate decreased interindividual variability. However, the best fit was obtained using the absolute dose, and when weight was included as a covariate for clearance (CL) and volume of distribution ( V ). The final parameter estimates were: CL 6.41 ml h -1 kg -1 ± 0.5 51% and V 65.4 ml kg -1 ± 0.5 27% (population mean ± 0.5 interindividual variability). The area under the curve at a dose of 60 mg m -2 was 231 mg l -1 h. Conclusions In comparison with free daunorubicin, Daunoxome ® shows a low volume of distribution, a lower clearance and a lower interindividual variability in these parameters. This might be advantageous in reducing the variability in exposure to the drug.

show abstract

“…Therefore, liposomes have been used as carriers of many kinds of molecules. For the main purposes of reducing side effects and targeting, many anti-cancer agents, such as doxorubicin [10][11][12][13][14], daunorubicin [15,16], annamycin [17], cisplatin derivatives [18], vincristine [19,20], paclitaxel [21,22], camptothecin derivatives [23,24], 5-fluorouracil derivatives [25,26] and so on have been encapsulated in liposomes. Furthermore, anthracyclines and some other agents are quite favorable for liposomal formulation, since these agents can be trapped in pre-formed liposomes with about hundred percent trapping efficiency by remote-loading method [27].…”

Section: Liposomal Applications In Ddsmentioning

confidence: 99%

“…. Biodistribution of PGlcUA-liposomes with various sizes imaged by PET [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. F]FDG-labeled PGlcUA-liposomes with various sizes composed of DPPC, cholesterol, and PGlcUA (4:4:1 as a molar ratio) were prepared.…”

mentioning

confidence: 99%

Evaluation of Drug Targeting Strategies and Liposomal Trafficking

Oku¹,

Tokudome²,

Asai³

et al. 2000

CPD

View full text Add to dashboard Cite

Liposomes, that are biodegradable and essentially non-toxic, can encapsulate both hydrophilic and hydrophobic materials, and are utilized as drug carriers for drug delivery systems (DDS). Recent progress in gene technology provides a novel modality of therapy for various diseases with a variety of newlydeveloped cationic liposomes. Delivery of agents to the reticuloendothelial system (RES) is easily achieved since most conventional liposomes are trapped by the RES. For the purpose of delivery of agents to target organs other than RES, long-circulating liposomes have been developed by modifying the liposomal surface. Understanding of the in vivo dynamics of liposome-carried agents is required to evaluate the bioavailability of drugs encapsulated in liposomes. In this review, we focus on the in vivo trafficking of liposomes visualized by positron emission tomography (PET) and discuss the characteristics of liposomes that affect the targeting of drugs in vivo.

show abstract

Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: Implications for liposome-encapsulated daunorubicin

Cited by 22 publications

References 27 publications

Liposome-Nanogel Structures for Future Pharmaceutical Applications

Liposome-Nanogel Structures for Future Pharmaceutical Applications

Population pharmacokinetics of liposomal daunorubicin in children

Evaluation of Drug Targeting Strategies and Liposomal Trafficking

Contact Info

Product

Resources

About